The study, led by Gianni Binotto of the University of Padova and Carmen Fava of the University of Turin, together with colleagues from major Italian haematology centres in Milan, Turin, Bari, Pavia and Bologna, focused on six adult patients with Philadelphia chromosome–positive chronic myeloid leukaemia in chronic phase. This form of leukaemia is defined by a characteristic genetic swap between chromosomes 9 and 22, which creates the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase. It is this rogue enzyme that tyrosine kinase inhibitors are designed to block, and the Philadelphia chromosome serves as the molecular fingerprint of the disease. All six patients in the series had already been exposed to at least two prior tyrosine kinase inhibitors and had either become resistant to them or suffered intolerable side effects, placing them among the most challenging cases that clinicians encounter in routine practice.

What set these patients apart was not only their treatment history but their overall health profile. The cohort carried a substantial burden of comorbidities, predominantly cardiovascular in nature. Hypertension, peripheral arterial disease, ischaemic heart disease and metabolic disorders featured prominently among their conditions. This detail matters because several first- and second-generation tyrosine kinase inhibitors, notably nilotinib and ponatinib, have been associated with arterial occlusive events, including heart attacks, strokes and peripheral vascular complications. For patients whose blood cancer is under control but whose arteries are compromised, the choice of therapy becomes a delicate balancing act between suppressing the leukaemia and protecting the cardiovascular system. Asciminib, with its distinctive mechanism of action, has been proposed as a particularly attractive option for exactly this population.

The reason lies in the drug’s unusual binding mode. Whereas earlier tyrosine kinase inhibitors target the ATP-binding site of the ABL1 kinase, asciminib selectively targets the myristoyl pocket, a regulatory region of the protein that is otherwise not exploited by any other approved drug in the class. This allosteric mechanism gives asciminib high specificity for its target and is thought to underpin its potentially improved safety profile. Because the myristoyl pocket is a distinct structural feature of ABL1, the drug can remain active against certain mutations that confer resistance to ATP-site competitors. Among these is the notorious T315I mutation, often described as the most formidable resistance mutation in chronic myeloid leukaemia, which has historically limited treatment options dramatically. Asciminib’s efficacy has been demonstrated in both clinical trials and real-world settings, including heavily pretreated patients and those carrying the T315I mutation, making it a valuable addition to the therapeutic arsenal.

In the Italian case series, asciminib was administered for a median duration of 16.5 months, providing a meaningful window in which to observe both efficacy and tolerability. The results were strikingly consistent. All six patients achieved or maintained clinically meaningful molecular responses, including major molecular responses and deep molecular responses. These endpoints are measured by tracking the level of BCR-ABL1 transcript in the blood using sensitive polymerase chain reaction assays, and deeper responses correlate with better long-term outcomes and, in some cases, the possibility of treatment-free remission. For patients who had already cycled through multiple therapies without success, the ability of asciminib to induce or sustain such responses represents a significant clinical benefit.

Equally important was the drug’s tolerability. Treatment was well tolerated across the cohort, with no discontinuations due to adverse events. No arterial occlusive events were observed, and no significant cardiovascular worsening occurred during the observation period. This is a notable finding given the cardiovascular vulnerability of the patients involved. Even more remarkably, no haematologic toxicity was recorded, even in a patient with underlying bone marrow hypoplasia, a condition in which the bone marrow’s capacity to produce blood cells is already diminished. Myelosuppression is a common concern with many anticancer therapies, and the absence of this toxicity in a compromised patient suggests that asciminib’s high target specificity translates into a genuinely gentler profile at the level of normal blood-forming tissue.

The authors are careful to frame these observations appropriately. With only six patients, the series cannot deliver the statistical power of a randomised trial, and the findings are presented as a summary of the drug’s clinical data alongside real-world experience rather than as definitive evidence. Nevertheless, the study argues that real-world data of this kind play an essential role in supporting treatment decisions, because patients seen in everyday practice are often older, more comorbid and more heavily pretreated than those enrolled in pivotal clinical trials. Regulatory trials typically exclude individuals with uncontrolled hypertension, prior arterial events or reduced bone marrow reserve, precisely the characteristics that defined this Italian cohort. Demonstrating that asciminib can be used safely and effectively in such patients fills an important evidence gap that trial data alone cannot address.

The broader context of chronic myeloid leukaemia treatment makes these findings resonate. Since the introduction of imatinib at the turn of the millennium, survival in chronic myeloid leukaemia has risen to near-normal life expectancy for many patients, turning a fatal disease into a chronic condition managed with daily oral therapy. But this success has created its own challenges: patients now live for decades with their disease and their medication, so long-term tolerability, cardiovascular safety and quality of life have become central concerns. Second-generation inhibitors improved response rates but introduced new toxicity profiles, and resistance mutations continue to emerge. Drugs that combine deep molecular activity with a favourable cardiovascular and haematologic safety profile address the most pressing unmet needs in the field, particularly for the growing population of long-term survivors with age-related comorbidities.

Asciminib’s allosteric mechanism also represents a conceptual milestone in targeted cancer therapy. Rather than competing with ATP at the active site, the drug locks the kinase into its inactive conformation by engaging a pocket used naturally by the protein’s own regulatory lipid, myristate. This approach, sometimes described as a STAMP inhibitor, an acronym for specifically targeting the ABL myristoyl pocket, illustrates how structural biology can be exploited to design molecules with exquisite selectivity. The Italian case series adds a practical, bedside-level dimension to this molecular story, showing that the elegance of the mechanism is reflected in clinical outcomes for patients who have few alternatives left.

For clinicians managing chronic myeloid leukaemia, the message from this small study is one of cautious encouragement. In a real-world cohort of heavily pretreated patients with substantial comorbidity burden, asciminib demonstrated sustained efficacy and a favourable safety profile, with cardiovascular tolerability standing out as a particular strength. The authors conclude that these findings reinforce the potential role of asciminib for patients with resistance or intolerance to multiple tyrosine kinase inhibitors, as well as for those at high cardiovascular risk. As more real-world data accumulate across centres and countries, the picture of who benefits most from this allosteric inhibitor will continue to sharpen, helping physicians tailor therapy to the individual patient rather than to the average trial participant. For the six Italian patients documented here, and for the many others like them worldwide, that individualisation may make all the difference between merely surviving with leukaemia and truly living well with it.

Subject of Research: Real-world efficacy and safety of the allosteric BCR-ABL1 inhibitor asciminib in heavily pretreated chronic myeloid leukaemia patients

Article Title: Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overview

Article References: Binotto, G., Cattaneo, D., Di Biase, F., Ditonno, P., Elena, C., Restuccia, R., & Fava, C. (2026). Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overview. Annals of Hematology. https://doi.org/10.1007/s00277-026-07284-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07284-7

Keywords: asciminib, chronic myeloid leukaemia, tyrosine kinase inhibitors, BCR-ABL1, myristoyl pocket, cardiovascular safety, molecular response, T315I mutation, real-world evidence, haematology, drug resistance, Annals of Hematology

BCR-ABL1 is the fusion protein born from the Philadelphia chromosome, the hallmark genetic abnormality of chronic myeloid leukemia and a subset of B-cell acute lymphoblastic leukemia. First described in landmark reviews by Goldman and Melo, the fusion fuses the BCR gene on chromosome 22 with the ABL1 tyrosine kinase gene on chromosome 9, producing a constitutively active kinase that drives uncontrolled proliferation and survival of white blood cells. Tyrosine kinase inhibitors were designed to slip into the ATP-binding pocket of ABL1 and freeze the enzyme in an inactive state. In structural studies of the kinase domain, including work by Cowan-Jacob and colleagues, imatinib and related compounds achieve exactly that. And yet, in patients, the kinetics of treatment response are markedly slower than direct enzyme inhibition would predict, an effect sometimes described as target sluggishness.

The new research reframes this sluggishness as an emergent property of how BCR-ABL1 organizes itself inside the cell. Rather than floating freely through the cytoplasm as isolated molecules, the team found that BCR-ABL1 molecules condense into dense, membraneless assemblies reminiscent of liquid droplets. These condensates form through multivalent, weak interactions among intrinsically disordered regions of the protein, the same class of physical chemistry that governs the formation of cellular structures such as nucleoli, stress granules and P bodies. The study connects this condensate behavior directly to therapeutic response: when BCR-ABL1 resides within these droplets, the local molecular environment becomes a physical barricade that slows the entry and action of tyrosine kinase inhibitors.

The concept of phase separation has transformed cell biology over the past decade. In a widely cited 2018 paper in Cell, Qamar and colleagues demonstrated that low-complexity protein domains can undergo liquid-liquid phase separation, creating compartments whose material properties dictate how molecules exchange with the surrounding cytoplasm. The new study applies this framework to cancer signaling for the first time in the context of targeted therapy. The authors showed that disrupting the conditions that promote condensate formation made BCR-ABL1 more accessible to drugs, while conditions that stabilized the droplets exaggerated the sluggish response. The droplet, in effect, functions as a microscopic shelter: drug molecules can reach the droplet surface, but penetrating the dense interior to reach every kinase molecule takes far longer than engaging freely diffusing protein.

Technically, the researchers combined protein biochemistry with cellular assays and clinical material. They purified BCR-ABL1 protein and observed its condensation behavior in solution, finding that the protein spontaneously demixes from the aqueous phase to form spherical droplets that fuse with one another and exchange internal contents, hallmarks of a liquid state. In cells, they visualized BCR-ABL1 condensates and correlated their abundance with the speed and completeness of kinase inhibition after tyrosine kinase inhibitor treatment. Crucially, the team collected bone marrow and blood samples from patients with BCR-ABL1-positive leukemia through collaborations with clinicians at Zhejiang Cancer Hospital and the First Hospital of China Medical University, allowing them to test whether condensate behavior in patient-derived cells tracked with treatment response.

The clinical implications of this reframing are substantial. Resistance to tyrosine kinase inhibitors has traditionally been attributed to kinase domain mutations, most famously the T315I substitution that abolishes imatinib binding, or to the persistence of leukemic stem cells that are intrinsically insensitive to the drugs. Studies such as those by Braun and colleagues and by Schneider and colleagues in Nature Cancer have catalogued the biology of these persistent cells, which survive initial therapy and fuel relapse. The phase separation model adds an entirely orthogonal mechanism: a cell can carry a completely drug-sensitive kinase and still mount a delayed response simply because its target protein is packaged inside droplets that physically exclude or retard drug penetration. This innate, non-genetic sluggishness could explain why a measurable fraction of cells in every treated patient survives the earliest hours and days of therapy without carrying any resistance mutation at all.

The finding also resonates with earlier structural and biochemical work on the ABL1 kinase. Structures of ABL1 bound to imatinib, dasatinib and nilotinib published by Tokarski and colleagues revealed exactly how these compounds lock the kinase in its inactive conformation, and kinetic studies showed rapid association rates in purified systems. The paradox between fast in vitro inhibition and slow cellular response now finds a candidate resolution: the purified enzyme in a test tube has no condensate, no barrier and no sluggishness, while the same enzyme inside a leukemic cell is wrapped in a liquid compartment that throttles drug access. Zhao and colleagues’ early structural characterization of the BCR-ABL1 complex, and Smith and colleagues’ dissection of its signaling architecture, provided the molecular map; phase separation now supplies the cellular geography that shapes how drugs navigate that map.

From a therapeutic standpoint, the study suggests that modulating condensate properties could become a strategy to sensitize leukemic cells to existing drugs. If the physical barrier created by BCR-ABL1 condensates is a principal cause of sluggish drug response, then agents that dissolve or destabilize the droplets, or that alter the material properties of the condensate so that small molecules diffuse through it freely, could accelerate and deepen the effect of tyrosine kinase inhibitors. Conversely, the work raises a caution for drug development: potency measured against purified kinase may systematically overestimate how quickly a compound will work in a cell whose target is phase-separated. Screening platforms that incorporate condensate-relevant conditions could help identify compounds that retain efficacy against droplet-sequestered targets, particularly for B-cell acute lymphoblastic leukemia, where early response kinetics strongly influence long-term outcome, as population studies by Qin and colleagues and reports by Ravandi and Molica have documented.

The broader significance extends beyond a single kinase or a single disease. Cancer biologists have increasingly recognized that many oncogenic proteins contain the disordered, multivalent regions that drive phase separation, and that signaling complexes such as those assembled by fusion oncoproteins, including the EML4-ALK and NUP98 fusions studied by Dixon and colleagues in engineered systems, may exploit condensation to amplify and sustain their signals. The BCR-ABL1 study demonstrates that this same organizational principle can also serve as a defensive architecture against therapy. Pendergast and colleagues’ classic 1991 work showed that BCR sequences activate ABL1 tyrosine kinase; three decades later, the new findings suggest that those same BCR-derived regions may coil the fusion protein into droplets that protect the activated kinase from the drugs designed to silence it.

For patients with chronic myeloid leukemia, tyrosine kinase inhibitors have converted a uniformly fatal disease into a manageable chronic condition, and a minority of patients now attempt treatment-free remission under close monitoring. Yet discontinuation fails in a substantial fraction, and persistent cells endure for years. By exposing the physical mechanism behind innate sluggishness, this research opens a new front in the effort to eliminate residual disease: rather than only designing better inhibitors, oncologists may one day prescribe drugs that strip away the droplet shield itself. The image of a cancer protein hiding inside a liquid droplet is a vivid one, and it captures a larger truth about modern biology. Cancer is not only a disease of genes and pathways but of physical organization, and conquering it may require manipulating not just what proteins do, but where and how they gather inside the cell.

Subject of Research: Phase-separated BCR-ABL1 condensates that delay the response of leukemic cells to tyrosine kinase inhibitor therapy

Article Title: Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy

Article References: Li, G., Wu, J., He, Z., Zhao, J., Chen, H., Zhou, J., Zhang, Q., Wang, Z., Li, Q., & Jiang, P. (2026). Phase separation drives the innate sluggishness of BCR-ABL1 in response to targeted therapy. Cell Research. https://doi.org/10.1038/s41422-026-01286-w

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01286-w

Keywords: BCR-ABL1, phase separation, chronic myeloid leukemia, tyrosine kinase inhibitors, condensates, imatinib, targeted therapy, leukemia, drug resistance, liquid-liquid phase separation, oncology, cell biology

The platform, named HOMEBRED for highly sensitive and specific omnipresent multiplex endonuclease-based reliable detection, is built on the SHERLOCK architecture that harnesses the CRISPR-associated protein Cas13a. When Cas13a finds the RNA sequence its guide molecule instructs it to find, it does not merely cut the target; it shreds any nearby RNA indiscriminately. This collateral cleavage activity is the engine of the assay. Synthetic RNA reporters carrying a fluorescent dye and a quencher float in the reaction; if the target is present, the reporters are cleaved, the fluorescence escapes, and the result can be read with the naked eye under an inexpensive handheld blue light or on paper-based lateral flow strips. No thermocycler, no sequencer, no fluorescence plate reader is required at any stage.

What separates HOMEBRED from earlier CRISPR diagnostics is the way its guide RNAs are chosen. Fragile crRNA target windows have been a chronic vulnerability in CRISPR-based tests, because a single mutation in the target sequence can silence the assay entirely, allowing an evolving pathogen to escape detection. The team addressed this with CaSilico, an automated computational pipeline that screens thousands of genome sequences to identify highly conserved, mutation-resistant regions. For foot-and-mouth disease virus, one of the most genetically variable livestock pathogens known, CaSilico analyzed 707 sequences of the conserved 3D gene across all seven serotypes, applying a 98 percent conservation threshold and yielding 41 candidate target sites from which two crRNAs were selected using stringent thermodynamic and specificity criteria.

That computational rigor proved consequential in practice. One of the two initial foot-and-mouth disease virus crRNAs, CR3D1, looked ideal on paper yet failed to detect the virus in the laboratory. When the researchers examined its predicted secondary structures in detail, they found that the centroid structure, not just the minimum free energy fold, deviated from the stable hairpin architecture that Cas13a requires for recognition. This failure mode has been observed by other groups, and the finding underscores a lesson increasingly clear in the field: guide RNA design must weigh thermodynamic structure predictions as carefully as sequence conservation. The redesigned guide, CR3D2, worked flawlessly, correctly classifying all 11 clinical samples in complete agreement with reference RT-qPCR, with detection limits reaching down to ten copies per microliter in both fluorescent and lateral flow formats.

Perhaps the most consequential demonstration involves brucellosis, a bacterial zoonosis that infects an estimated 300 million of the world’s 1.4 billion cattle and for which no human vaccine exists. Veterinary control programs face a stubborn problem known as DIVA, the inability to differentiate infected animals from vaccinated ones. A false positive in a vaccinated, high-breeding-value animal can trigger needless culling, while a missed infection lets the disease spread silently. HOMEBRED tackles this with a dual-crRNA architecture: one guide targets the conserved bcsp31 gene to detect the four major Brucella species, while a second exploits a deletion mutation in the narJ gene unique to the RB51 vaccine strain. In testing, the platform signaled every wild-type culture of B. melitensis, B. abortus and B. suis while remaining silent against the vaccine strain, achieving 100 percent concordance with reference PCR across all 14 samples tested.

The platform also ventures into oncology. BCR-ABL1 fusion transcripts, produced when chromosomes 9 and 22 break and rejoin, are the hallmark of chronic myeloid leukemia, and the specific transcript isoform a patient carries influences response to tyrosine kinase inhibitor therapy. HOMEBRED distinguished the e13a2, e14a2 and e1a2 isoforms using isoform-specific guide RNAs and recombinase polymerase amplification primers sharing a common reverse primer on the ABL1 gene. Validated against the KCL-22 and K-562 leukemia cell lines and 14 clinical samples, the assay matched Sanger sequencing in specificity and exceeded RT-qPCR in sensitivity. Strikingly, three samples that reference RT-qPCR had called negative were positive by HOMEBRED, and two patients were found to co-express two transcript types simultaneously, findings with direct implications for treatment selection and minimal residual disease monitoring.

Two reaction formats were compared head to head. The two-step assay runs amplification and detection in separate tubes, while the single-step format folds both into one pot, reducing handling time and contamination risk. For Brucella, the one-pot version matched the two-step version perfectly, but for foot-and-mouth disease virus it dropped to 77 percent agreement, missing three positives and losing roughly an order of magnitude in detection limit. The authors conclude that the two-step format remains the safer default when sensitivity is paramount, reserving the single-step format for targets where its performance is proven. All duplicate reactions across both formats achieved 100 percent qualitative concordance, 111 out of 111 pairs, a reproducibility figure that speaks to careful optimization.

The extraction-free capability is where HOMEBRED pushes furthest past the existing literature. Traditional purification, when skipped, usually devastates sensitivity because crude biological matrices carry enzymatic inhibitors such as hemin and polysaccharides. The team paired their assay with HUDSON, a method that heats samples with chemical reducers to destroy nucleases and release genetic material, and applied it directly to vesicular fluid and epithelial tissue from foot-and-mouth disease cases. Without any nucleic acid extraction, the workflow detected viral seedstock down to 3.23 times ten to the fourth plaque-forming units per milliliter by colorimetric readout and 3.23 times ten to the third by fluorescence, an improvement of up to two orders of magnitude over comparable extraction-free CRISPR assays. The strategic choice of epithelial tissue, which proves far more chemically compatible with the HUDSON reaction than blood or feces, appears central to this performance.

Robustness against real-world genetic drift was verified by sequencing. Sanger analysis of foot-and-mouth disease virus samples confirmed that the computationally designed target region stayed fully conserved across strains, with a single substitution in one sample that failed to impair detection. Two leukemia clinical samples harbored point mutations inside the protospacer region, and HOMEBRED still called both correctly with no signal loss. The choice of Cas13a over the Cas12a enzymes used in several rival platforms also matters here: Cas13a requires no protospacer adjacent motif, freeing guide design from target-site constraints that are particularly restrictive when isolating the narrow junctions of fusion transcripts, and its vigorous trans-cleavage activity sustains signal generation even at suboptimal temperatures.

The authors acknowledge limits. Clinical isolates of B. canis could not be physically tested due to regional availability, so the team verified the assay against synthetic DNA carrying the identical conserved bcsp31 target domain, supported by sequence alignments showing 100 percent identity. No accessible cell line expressing the minor e1a2 transcript was available for extended in vitro benchmarking. Future work, they write, should prioritize lyophilized reagent formulations to round out farm-level deployment. Even with those caveats, HOMEBRED demonstrates that a single CRISPR platform, guided by automated conserved-region design and read by nothing more sophisticated than a handheld blue light, can deliver sensitivity on par with PCR across livestock pathogens, zoonotic bacteria, respiratory viruses and leukemia biomarkers, a convergence that could materially narrow the diagnostic gap between well-resourced laboratories and the places where early detection matters most.

Subject of Research: A CRISPR-Cas13a diagnostic platform enabling instrument-free detection of infectious agents and oncogenic mutations

Article Title: HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations

Article References: Asadbeigi, A., Fazilaty, H., Saffari, M., Shirkoohi, R., Modarressi, M. H., Salehi, A., & Bakhtiarizadeh, M. R. (2026). HOMEBRED: A unified CRISPR platform for field-ready shadowing of infectious agents and oncogenic mutations. iScience, 29(10), Article 117532. https://doi.org/10.1016/j.isci.2026.117532

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117532

Keywords: CRISPR diagnostics, Cas13a, SHERLOCK, HOMEBRED, foot-and-mouth disease virus, brucellosis, SARS-CoV-2, BCR-ABL1, chronic myeloid leukemia, recombinase polymerase amplification, DIVA, point-of-care testing